Skip to main content


Fig. 2 | EJNMMI Research

Fig. 2

From: The clinical safety, biodistribution and internal radiation dosimetry of [18F]AH113804 in healthy adult volunteers

Fig. 2

Representative PET Maximum Intensity Projections (MIP) following administration of AH113804 (18F) Injection. Representative OSEM PET Maximum Intensity Projection (MIP) of a subject 4 and b subject 2 following administration of AH113804 (18F) Injection. Acquisitions shown were performed at approximately (left to right) 0, 0.2, 0.5, 1.0, 2.5 and 3.7 h p.i. and features of note include the injection site on the left arm, the initial uptake in the heart and liver, clearance through the kidneys and the appearance of the gallbladder in later time frames. In subject 2, artefacts around the bladder are also apparent where the bladder activity is greatest

Back to article page